Lidocaine and Perioperative Cytokine Levels in Blood and Cerebrospinal Fluid in Cerebral Aneurysm Patients

Sponsor
Clinical Hospital Centre Zagreb (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT03823482
Collaborator
(none)
40
1
2
33.1
1.2

Study Details

Study Description

Brief Summary

Cerebral aneurysm surgery has significant mortality and morbidity rate. Inflammation plays a key role in the pathogenesis of intracranial aneurysms, their rupture, subarachnoid haemorrhage and neurologic complications. Brain injury activates immune cells and triggers cytokine release. Cytokine level in blood and cerebrospinal fluid is an indicator of inflammatory response. Cytokines contribute to secondary brain injury and can worsen the outcome of the treatment. Preventing secondary brain injury by modulating inflammatory response represents a therapeutic target. Lidocaine is local anesthetic that can be used in neurosurgery for regional anesthesia of the scalp and for topical anesthesia of the throat prior to direct laryngoscopy and endotracheal intubation. Except analgetic, lidocaine has systemic anti-inflammatory and neuroprotective effect. It acts through several mechanisms on various types of immune cells producing immunosuppressing effect. Lidocaine can act on activated microglia within central nervous system causing attenuation of immune response.

Primary aim of this prospective randomized trial is to determine influence of lidocaine administration on inflammatory cytokine levels in serum and cerebrospinal fluid during and following cerebral aneurysm surgery. Secondary aim is to determine possible correlation between levels of cytokines and incidence of neurologic and infectious postoperative complications. For that purpose, postoperative neurological clinical status will be recorded. Signs of vasospasm and pathological postoperative brain CT scan findings will be recorded. Incidence of meningitis, pneumonia and sepsis in postoperative period will also be analyzed.

Hypothesis of this trial is that lidocaine administration during cerebral aneurysm surgery would significantly change levels of pro-inflammatory cytokines in cerebrospinal fluid and serum. Lower concentrations of pro-inflammatory cytokines can possibly contribute to better outcome and significantly lower incidence of postoperative complications. Enzyme-immunochemical analysis will be used to measure levels of interleukin-1β, interleukin-6 and tumor necrosis factor-α in cerebrospinal fluid and serum. Investigation group will have, during cerebrovascular surgery under general anesthesia, regional anesthesia of the scalp and topical anesthesia of the throat prior to laryngoscopy, all done with lidocaine. Control group will have general anesthesia without lidocaine administration.

Condition or Disease Intervention/Treatment Phase
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Effect of Regional Anesthesia With Lidocaine on Perioperative Levels of Interleukin-1β, Interleukin-6 and Tumor Necrosis Factor-α in Blood and Cerebrospinal Fluid in Cerebral Aneurysm Patients
Actual Study Start Date :
Mar 1, 2019
Anticipated Primary Completion Date :
Mar 1, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Lidocaine group

Participants in lidocaine group, following induction to general anesthesia, will have lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation. Maximum dosage of lidocaine won't exceed 400 mg.

Drug: Lidocaine
Administration of lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation.
Other Names:
  • Regional anesthesia
  • No Intervention: Control group

    Participants in control group will have general anesthesia without lidocaine administration.

    Outcome Measures

    Primary Outcome Measures

    1. Change in concentrations of interleukin-1β [Up to 24 hours after anesthesia induction.]

      Concentrations of IL-1β in pg/ml in cerebrospinal fluid and serum measured by enzyme-linked immunosorbent assay

    2. Change in concentrations of interleukin-6 [Up to 24 hours after anesthesia induction.]

      Concentrations of IL-6 in pg/ml in cerebrospinal fluid and serum measured by enzyme-linked immunosorbent assay

    3. Change in concentrations of tumor necrosis factor α [Up to 24 hours after anesthesia induction.]

      Concentrations of TNF-α in pg/ml in cerebrospinal fluid and serum measured by enzyme-linked immunosorbent assay

    Secondary Outcome Measures

    1. Incidence of new motoric deficit [Up to one week postoperatively]

      Clinical assessment of neurologic status incidence of generalized epileptic seizure, incidence of vasospasm, pathological finding on brain computerized tomography ( ischemia, edema, bleeding, hydrocephalus).

    2. Incidence of generalized epileptic seizure [Up to one week postoperatively]

      Clinical assessment to diagnose generalized epileptic seizure

    3. Incidence of vasospasm [Up to one week postoperatively]

      Flow velocity over middle cerebral artery more than 180 cm/s measured by transcranial ultrasound

    4. Incidence of pathological computerized tomography brain scan [Up to one week postoperatively]

      Findings of edema, ischemia, bleeding or hydrocephalus on brain CT scan

    Other Outcome Measures

    1. Incidence of meningitis, pneumonia and sepsis [Up to one week postoperatively]

      Clinical signs and laboratory findings for diagnosing infectious complications

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • ASA ( American Society of Anesthesiologists) grading status I-III,

    • scheduled for cerebral aneurysm surgery under general anesthesia,

    • signed informed consent for participating in the research.

    Exclusion Criteria:
    • poorly controlled chronic or acute cardiovascular, respiratory or autoimmune disease,

    • acute infectious disease,

    • renal or hepatic insufficiency,

    • preoperative Glasgow Coma Scale score lower than 15,

    • allergic reaction to any of the medications in protocol,

    • pregnancy

    • refusal to participate in the research.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UHCZagreb Zagreb Croatia 10000

    Sponsors and Collaborators

    • Clinical Hospital Centre Zagreb

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Marijana Matas, Principal Investigator, Clinical Hospital Centre Zagreb
    ClinicalTrials.gov Identifier:
    NCT03823482
    Other Study ID Numbers:
    • 51
    First Posted:
    Jan 30, 2019
    Last Update Posted:
    Nov 12, 2020
    Last Verified:
    Nov 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Marijana Matas, Principal Investigator, Clinical Hospital Centre Zagreb
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 12, 2020